Browse TNFRSF8

Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm.
Domain PF00020 TNFR/NGFR cysteine-rich region
Function

Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.

> Gene Ontology
 
Biological Process GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0009612 response to mechanical stimulus
GO:0032496 response to lipopolysaccharide
GO:0032639 TRAIL production
GO:0032640 tumor necrosis factor production
GO:0032679 regulation of TRAIL production
GO:0032680 regulation of tumor necrosis factor production
GO:0032759 positive regulation of TRAIL production
GO:0032760 positive regulation of tumor necrosis factor production
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042533 tumor necrosis factor biosynthetic process
GO:0042534 regulation of tumor necrosis factor biosynthetic process
GO:0042535 positive regulation of tumor necrosis factor biosynthetic process
GO:0045553 TRAIL biosynthetic process
GO:0045554 regulation of TRAIL biosynthetic process
GO:0045556 positive regulation of TRAIL biosynthetic process
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071356 cellular response to tumor necrosis factor
GO:0071496 cellular response to external stimulus
GO:0071706 tumor necrosis factor superfamily cytokine production
GO:1903555 regulation of tumor necrosis factor superfamily cytokine production
GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production
Molecular Function GO:0005031 tumor necrosis factor-activated receptor activity
GO:0005035 death receptor activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFRSF8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFRSF8 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18230757LymphomaImmunotherapy targetHuman antibody RNase fusion protein targeting CD30+ lymphomas. Targeted RNases (TRs) are immunoenzymes with ribonucleases as cytotoxic effector domains, which are less immunogenic as plant or bacterial toxin components of classical immunotoxins. Proliferation of the CD30+ lymphoma cell line Karpas-299 was strongly inhibited by CD30-specific huTR protein (IC50=3.3 nM).
19789316Primary Cutaneous Anaplastic Large Cell Lymphoma; Lymphomatoid PapulosisEssential for immunotherapyThe overall objective response rate [complete response (CR) + partial response (PR)] was 70% (16 of 23 patients): 10 patients achieved a CR and another 6 patients achieved a PR. Overall, clinical benefit of SGN-30, as assessed by achieving a response to therapy or stable disease (CR + PR + stable disease), was shown by 87% of patients during the study, including all patients with pc-ALCL or LyP and two thirds of patients with T-MF or with multiple clinical diagnoses. Nine of the 10 patients who achieved a CR and 5 of the 6 patients who achieved a PR were in remission at their follow-up evaluation (median duration, 84 days).
24916470adenocarcinomaInhibit immunity (T cell function); decrease the efficacy of immunotherapyBrentuximab vedotin represents a first-in-class ADC directed against CD30(+) malignancies.
23974006Anaplastic Large Cell Lymphoma; Hodgkin LymphomaInhibit immunity (T/NK cell function); immunotherapy targetImmunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. CD30 is highly expressed on Hodgkins lymphoma and anaplastic large cell lymphoma, making it an attractive target for therapy. The multivalent aptamer was able to induce oligomerization of CD30 receptors and, in effect, activate downstream signaling, which led to apoptosis of ALCL cells.
28805662Anaplastic Large Cell Lymphoma; Hodgkin LymphomaInhibit immunity; Immunotherapy targetTargeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical success. CD30.CAR-Ts are safe and can lead to clinical responses in patients with HL and ALCL, indicating that further assessment of this therapy is warranted.
24395820MelanomaInhibit immunity (T cell function)Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Phenotypic profiling demonstrated that CD30(+) lymphocytes comprised a broad population of suppressive or exhausted immune cells, such as CD4(+)Foxp3(+) or PD1(+) subpopulations and CD4(-)CD8(-) T cells.
17515574Hodgkin LymphomaInhibit immunityPhase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. MDX-060 is a human anti-CD30 immunoglobulin (Ig) G1kappa monoclonal antibody that inhibits growth of CD30-expressing tumor cells in preclinical models.
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFRSF8 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFRSF8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6750.099
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-10.144
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4370.458
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1180.83
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2690.793
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0670.958
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.520.372
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8910.302
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0570.95
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6290.151
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3650.522
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1610.513
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFRSF8 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.76.8-3.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.78.5-4.80.66
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFRSF8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFRSF8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFRSF8.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFRSF8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFRSF8 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFRSF8 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFRSF8
Nametumor necrosis factor receptor superfamily, member 8
Aliases KI-1; CD30; D1S166E; CD30L receptor; Ki-1 antigen; cytokine receptor CD30; lymphocyte activation antigen CD3 ......
Chromosomal Location1p36
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFRSF8 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting TNFRSF8.
ID Name Drug Type Targets #Targets
DB08870Brentuximab vedotinBiotechTNFRSF81